Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066554 | 0.87 | ALDH1A1 (0.42) | KDM4EALDH1A1HPGDMAPTCYP2C9 | |
| SCHEMBL1175088 | 0.78 | NR4A2 (0.44) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL186399 | 0.76 | NR4A2 (0.42) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL2200423 | 0.72 | GPR55 (0.42) | KDM4EALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL2064328 | 0.71 | ALDH1A1 (0.49) | KDM4EALDH1A1HPGDMAPTCYP2C9 | |
| SCHEMBL4150903 | 0.70 | CYP2C9 (0.40) | KDM4EALDH1A1HPGDMAPTCYP2C9 | |
| Diphenylether SCHEMBL8651099 | 0.69 | LTA4H (0.43) | ALDH1A1MAPTMEN1KMT2AADORA2A | |
| SCHEMBL28691779 | 0.69 | KMT2A (0.50) | MAPTMEN1KMT2AADORA2AADORA1 | |
| SCHEMBL4462189 | 0.69 | NR4A2 (0.53) | KDM4EALDH1A1HPGDMAPTCYP2C9 | |
| SCHEMBL31124 | 0.69 | CYP3A4 (0.58) | KDM4EALDH1A1HPGDMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222667-B1 | NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2013-02-20 | — | — | EP | disclosed |
| CN-101896482-B | Thiophene derivatives as S1P1/EDG1 agonists | ACTELION PHARMACEUTICALS LTD | 2013-01-09 | — | — | CN | disclosed |
| US-8148410-B2 | Thiophene derivatives as agonists of S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-04-03 | — | — | US | disclosed |
| CN-101896482-A | Thiophene derivatives as S1P1/EDG1 agonists | ACTELION PHARMACEUTICALS LTD | 2010-11-24 | — | — | CN | disclosed |
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-10-14 | — | — | US | disclosed |
| EP-2222667-A2 | NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009074950-A2 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | S1PR1, S1PR3, S1PR5 | KDM4E 1738/4885ALDH1A1 1141/4885HPGD 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.